Cytek Biosciences (CTKB) vs. Its Competitors Head to Head Contrast

Cytek Biosciences (NASDAQ:CTKB – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it contrast to its peers? We will compare Cytek Biosciences to similar companies based on the strength of its earnings, profitability, analyst recommendations, risk, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cytek Biosciences and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytek Biosciences 1 1 2 0 2.25
Cytek Biosciences Competitors 957 3193 5530 179 2.50

Cytek Biosciences currently has a consensus target price of $5.67, suggesting a potential downside of 2.97%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 0.10%. Given Cytek Biosciences’ peers stronger consensus rating and higher possible upside, analysts plainly believe Cytek Biosciences has less favorable growth aspects than its peers.

Insider and Institutional Ownership

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 54.0% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 10.4% of Cytek Biosciences shares are held by company insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Cytek Biosciences has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Cytek Biosciences’ peers have a beta of 0.93, meaning that their average share price is 7% less volatile than the S&P 500.

Profitability

This table compares Cytek Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cytek Biosciences -39.10% -13.13% -9.56%
Cytek Biosciences Competitors -487.63% 79.17% -12.95%

Earnings and Valuation

This table compares Cytek Biosciences and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cytek Biosciences $201.49 million -$66.54 million -9.27
Cytek Biosciences Competitors $2.26 billion $55.11 billion -7.73

Cytek Biosciences’ peers have higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Cytek Biosciences peers beat Cytek Biosciences on 9 of the 13 factors compared.

About Cytek Biosciences

(Get Free Report)

Cytek Biosciences develops, manufactures and sells cell analysis instruments and related products used by researchers and clinical laboratories. Its systems use flow cytometry to analyze cells and other particles, supporting work in areas such as immunology, oncology and infectious disease research. The company’s product portfolio includes the Aurora and Northern Lights spectral flow cytometry systems and Amnis imaging flow cytometers. Cytek also offers reagents, software, technical support and other services that help customers prepare samples, collect and interpret data, and maintain their instruments.

Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.